We propose that DDX11 provides a mechanism of replication stress tolerance, which sustains survival of cancers, including BRCA1- and BRCA2-deficient cells, and can be exploited therapeutically through the development of specific inhibitors of DDX11 helicase activity. The gene discussed is DDX11; the disease is cancer.